Jardine Matheson to Acquire Australia’s I-MED in $2.4 Billion Healthcare Deal

Australia’s healthcare sector saw another major shake-up on May 25, 2026, after Jardine Matheson announced plans to acquire I-MED Radiology Network in a $2.4 billion deal. The move highlights rising investor interest in diagnostic imaging and AI-powered healthcare services. 

I-MED handles millions of patient scans every year across Australia and New Zealand, making it a key player in the region. The acquisition also signals how healthcare technology and medical imaging are becoming some of the fastest-growing investment areas in 2026.

Key Details of the Jardine Matheson-I-MED Deal

Deal Size and Structure

On May 25, 2026, Hong Kong-based Jardine Matheson announced plans to acquire Australia’s I-MED Radiology Network in a deal valued at A$3.4 billion, or about $2.4 billion. The company will buy a 100% stake from private equity firm Permira and other shareholders. Reuters reported that the transaction is expected to close later in 2026 after regulatory approvals.

Financing Strategy

Jardine Matheson said the acquisition will be funded through a mix of cash reserves and debt financing. The company did not reveal the exact funding split. Analysts see this as part of Jardine’s broader strategy to reshape its portfolio toward healthcare and other long-term growth industries. The group recently completed the privatization of Mandarin earlier in 2026.

Why the Deal Stands Out in 2026 M&A Activity

The acquisition is already being viewed as one of the biggest healthcare deals in the Asia-Pacific region this year. It also highlights strong investor demand for healthcare infrastructure and AI-powered medical businesses. Healthcare diagnostics continues to attract major private equity and institutional investment in 2026.

Inside I-MED Radiology Network’s Business Model

Australia’s Largest Diagnostic Imaging Provider

I-MED is one of the largest medical imaging companies in Australia and New Zealand. The network operates more than 215 clinics and performs over 7 million patient procedures every year. Its services include MRI scans, CT imaging, ultrasound, nuclear medicine, and X-rays. The company has expanded rapidly under Permira since 2018, as demand for diagnostic testing has increased across hospitals and outpatient healthcare centers.

Why Is Teleradiology Growing So Fast?

Teleradiology allows doctors to review scans remotely. This service has become more important because many regions face shortages of radiologists. I-MED currently provides remote imaging services across Australia, New Zealand, and the United States. Industry analysts believe demand for digital healthcare services will continue rising over the next decade.

AI Integration Through Harrison.ai

The deal also includes I-MED’s minority stake in Harrison.ai. The company develops AI tools that help doctors analyze CT brain and chest scans faster. This gives Jardine exposure to one of healthcare’s fastest-growing technology segments.

Many investors now use advanced platforms like the Meyka AI stock analysis tool to track how AI-focused healthcare deals may impact long-term market trends.

Why Jardine Matheson Is Expanding Into Healthcare?

Strategic Shift Under CEO Lincoln Pan

This acquisition marks the first major deal under Jardine Matheson CEO Lincoln Pan, who took over in December 2025. Financial Times reported that the company is shifting toward an investment-focused business model centered on developed Asian markets. The I-MED acquisition supports that long-term strategy.

Jardine Matheson said on Monday it ‌has agreed to buy Australian medical imaging provider I-MED Radiology Network for a total enterprise value of A$3.4 billion ($2.4 billion), adding a major healthcare diagnostics business to the Hong Kong-based group.https://t.co/um427rTdmZ

— Gary Buckley™ (@myrddenbuckley) May 25, 2026

Why Healthcare Remains a Defensive Growth Sector?

Healthcare continues to attract investors because demand stays stable even during economic slowdowns. Aging populations, rising chronic disease cases, and higher use of preventive care are increasing demand for imaging services globally. Diagnostic healthcare companies also generate recurring revenue from patient procedures and hospital partnerships.

AI Healthcare Investments Becoming Mainstream

AI-driven healthcare has become a major investment theme in 2026. Medical imaging companies are using AI to improve scan accuracy, reduce reporting times, and lower operating costs. Analysts believe healthcare AI adoption will accelerate further as hospitals push for efficiency and faster patient care.

Financial Metrics and Valuation Analysis

EBITDA Multiple and Market Valuation

Jardine Matheson said the deal values I-MED at about 11.5 times forecast adjusted EBITDA for the financial year ending June 2026. Analysts say this reflects strong confidence in the company’s future growth potential and leadership in diagnostic imaging.

Revenue and Earnings Growth Trends

I-MED expanded strongly during Permira’s ownership. The business benefited from growing healthcare demand, AI adoption, and higher imaging volumes after the pandemic recovery period. Investors also expect future growth from regional expansion and digital imaging services.

Earnings Impact on Jardines

The company expects the transaction to be earnings-neutral during the first full year after closing but accretive afterward. Investors appeared optimistic, with Jardine Matheson shares rising after the announcement.

Final Words

Jardine Matheson’s $2.4 billion acquisition of I-MED shows how healthcare diagnostics and AI-powered medical imaging are becoming major investment priorities in 2026. The deal strengthens Jardines’ healthcare presence while giving it exposure to fast-growing radiology and AI technologies. 

As demand for digital healthcare services rises, I-MED could play a bigger role in the future of medical diagnostics across the Asia-Pacific region.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.